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Phagocytic cells  (neutrophils,  monocytes, and  macrophages)  possess  at  least 
two distinct receptors for the third component of complement, C3. Complement 
receptor  type  1 (CR1) 1 is specific for  C3b,  while complement receptor type 3 
(CR3) is specific for the C3b cleavage product iC3b (1).  In addition, monocytes 
may also express a  CRy-like receptor that is specific for the d  region of iC3b, 
C3d,g, and  C3d (2,  3).  CRI  and CR3  on  neutrophils and  monocytes promote 
phagocytosis  of  C3-coated  particles  mainly  by  promoting  adherence  of  the 
particle to the phagocyte's surface (4, 5). In contrast, complement receptors (CR) 
on human and mouse macrophages may promote both binding and phagocytosis 
of C3-coated  particles,  depending  on  the  in  vitro  or  in  vivo  conditions  from 
which  the  macrophages  were  obtained  (6-10).  The  data  on  CR  function  has 
been  derived  from  studies  using sheep  erythrocytes (E)  coated with  C3  using 
purified complement (C) components, mouse serum, or human serum. However, 
little is  known  about  the  actual  C3  fragments that  might be  encountered  by 
phagocytes in vivo. 
Detailed information is available on the sequence of events that occurs after 
C3b  has  been  fixed  to  a  particle's  surface  through  activation  of the  classical 
pathway (CP) or alternative pathway (AP) (reviewed in 11). The several compo- 
nents, C4-binding protein (12), factors H  and I  (13,  14), and erythrocyte (CR1) 
(15,  16),  play key roles  in  controlling the activation and propagation  of both 
complement  pathways, by  their ability to  convert  bound,  hemolytically active 
C3b into nonhemolytic fragments. In addition, it has become increasingly clear 
that the surface to which C3b becomes fixed plays a  critical role in the suscepti- 
bility of C3b to these control proteins. Current data suggests that particles which 
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can  activate  the  AP  do  so because  they  provide  a  protected  environment  for 
bound C3b (17-20), whereas CP activators do not. This protective environment 
promotes AP activation by favoring the binding of factor B rather than factor H 
to  C3b  (21,  22).  For  example,  sialic  acid  appears  to  be  the  critical  membrane 
component that prevents sheep E from being AP activators (22, 23). The surface 
components on  other particles,  or,  more importantly, on microorganisms,  that 
play a  role in determining whether or not the AP is activated have not yet been 
defined.  In addition,  these surface components could play an important role in 
determining  how  much  C3b  becomes  inactivated  to  iC3b  or  C3d,g,  and  how 
much C3b remains intact on the particle's surface. 
In the present study, two monoclonal antibodies, anti-C3c and anti-C3g,  were 
used to quantitate the deposition by serum ofC3b, iC3b, and C3d,g onto various 
particles and microorganisms. Antibody-coated sheep E, rabbit E (ER), yeast (Y), 
and  five  different  species  of  bacteria:  Escherichia  coli,  Staphylococcus  aureus, 
Haemophilus  influenzae  type b, Streptococcus pneumoniae type 3, and Streptococcus 
pyogenes,  were  examined.  Three  questions  were  addressed:  (a)  What  is  the 
number  of  C3  molecules  that  become  fixed  to  bacteria  and  other  particles 
opsonized in normal human serum; (b) what is the ratio of C3b to iC3b and/or 
C3d,g; and (c) what are the kinetics of C3b deposition and conversion to iC3b? 
The data show that the quantity of C3b fixed was dependent on the particle and 
the serum concentration,  while the ratio of C3b to iC3b was mainly dependent 
on  the  particle  or  bacterium,  iC3b  was  found  to  be  the  predominant  form of 
bound C3 on Y and E, while C3b was the predominant form of C3 on bacteria. 
The  importance  of these  observations as they relate  to complement activation 
and to host defense is discussed. 
Materials and  Methods 
Serum.  Blood was obtained from six normal donors and allowed to clot in glass tubes 
for 45  rain at  22°C.  The clots were rimmed with  wooden sticks,  and  then allowed to 
retract by incubation at 4°C for a further 45 rain. The clotted blood was centrifuged at 
8,000 g for 30 min to obtain serum. Serum from the six donors was pooled and aliquoted, 
and then was stored at -85°C until used. Serum from a patient with C7 deficiency (24) 
was processed and stored in an identical manner. Once thawed, serum was used immedi- 
ately for one experiment, and any remainder was discarded. One batch of pooled human 
serum (PHS) or the C7-deficient serum was used for all experiments reported in these 
studies. 
Particles.  Sheep  erythrocytes (E) stored  in  Alsever's solution  were coated with  IgG 
and IgM anti-sheep erythrocyte antibody (Cordis Laboratories, Miami, FL) according to 
the method of Kabat and Mayer (25). Antibodies were used at the recommended dilutions 
for optimal complement fixation (IgG, 1:200; IgM, 1:120). EIgM and EIgG were washed 
and  stored  in  3.5  mM  veronal  buffer, pH  7.2,  containing  1%  bovine serum albumin 
(BSA),  3.2% dextrose, 20 mM EDTA, and 0.2% sodium azide (BDVEA) (conductivity, 6 
mS at 22°C). ER were obtained from normal rabbits, washed three times in BDVEA, and 
were  stored  in  BDVEA  until  used.  Bakers  yeast  (Y)  was  processed  as  described  by 
Lachmann and Hobart (26) and stored in 0.15 M saline. 
Bacteria.  Five  species  of bacteria  were  used  in  these  experiments:  E.  coli, ATCC 
25922; hemolytic S. aureus, ATCC 25923; a clinical throat isolate of group A,/3 hemolytic 
S. pyogenes; a clinical blood isolate of S. pneumoniae type III; and a clinical blood isolate of 
H. influenzae type b. All species were kindly provided by the Microbiology Laboratory of 
North Carolina Memorial Hospital at the  University of North Carolina.  Cultures were 
maintained on agar plates and subcultured  once a  week. H.  influenzae  was cultured on 
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E. coli and S. aureus were grown in Tripticase soy broth and S. pyogenes and S. pneumoniae 
were grown in Todd-Hewitt broth (BBL Microbiological Systems, Becton, Dickinson & 
Co., Cockeysville MD); H. influenzae was grown in Mueller-Hinton broth (Difco Labora- 
tories,  Detroit,  MI)  containing  1%  isovitalex  (BBL  Microbiological  Systems)  and  1% 
hemin.  Before  use,  growth  curves  were  determined  on  each  bacterial  species  using 
standard procedures. Bacteria were obtained for experiments during the log phase of the 
growth curve. For some experiments, bacteria were obtained from log phase cultures and 
inactivated by heating at 65°C for  lh. S. pneumoniae  were heat killed in 0.4% formalin. 
Heat-killed bacteria  were washed  twice in saline and then stored  in 0.01  M  phosphate- 
buffered saline (PBS), pH 7.4, containing 0.02% sodium azide (PBSA). Heat-killed bacteria 
were standardized by counting in a Pertroff Hauser chamber. 
Opsonization.  For opsonization, freshly thawed PHS or C7D serum (for erythrocytes) 
was  diluted  in  veronal-buffered  saline  containing  0.5  mM  Mg  +÷  and  0.15  mM  Ca  ÷+ 
(VBS÷+).  ER and  EIgM were washed and standardized  to  1 x  108 E/ml in VBS  +÷, and 
EIgG were standardized  in  VBS  ++ containing 0.1%  gelatin (GVB++).  (GVB  +÷ was used 
for  EIgG to  minimize  aggregation  and  spontaneous  lysis  of these  cells.)  Y  cells  were 
standardized in VBS  ÷+ at  1.5 x  109 Y/ml.  Equal volumes of particles and diluted serum 
were  mixed  and  then  incubated  for  varying  periods  of time  at  37°C.  Control  tubes 
contained particles plus buffer only. At the end of the incubation period, E were diluted 
in BDVEA, washed three times, and resuspended in BDVEA to 5-7 x  10  ~ E/ml. Y were 
washed three times in cold PBS and then resuspended to 2 X  108 Y/ml in BDVEA. 
Bacteria were grown to log phase, at which time a sample was removed, diluted, and 
plated  on agar to determine  the  number  of colony-forming units  (CFU)  per  milliliter. 
The bacteria were aliquoted into several tubes and washed twice in saline.  1 ml of PHS 
(or saline for the control) was added to each pellet of bacteria, the bacteria were vigorously 
resuspended, and the tubes were then incubated at 37°C for varying periods of time. At 
the end of the incubation period, bacteria were washed twice in saline and resuspended 
to 2 mi in BDVEA. Heat-killed bacteria were opsonized in a similar manner. 
Antibodies.  Radiolabeled  IgG anti-C3c and anti-C3g were used to assess the number 
of bound C3b and  iC3b on the various particles  and  bacteria.  Ascites fluid containing 
anti-C3c  was  obtained  from  Bethesda  Research  Laboratories,  Gaithersburg,  MD,  and 
ascites fluid containing anti-C3g (clone 9) (27 and  28) was a  generous gift of Dr.  Peter 
Lachmann of the Medical Research Council, Cambridge, England. IgG was purified from 
ascites  by  sequential  precipitation  with  caprylic  acid  and  50%  ammonium  sulfate  as 
described previously (2).  The purified antibodies appeared as single bands after electro- 
1251  phoresis on sodium dodecyl sulfate (SDS)-polyacrylamide gels.  I-labeled IgG was pre- 
pared with Iodogen (Pierce Chemical Co., Rockford, IL) by the method of Fraker and 
Speck (29).  For each labeling,  0.25  mCi of ~5I were used for  100 ttg of IgG, to give a 
specific activity of 1-2 X  106 cpm/#g. 
Radioimmunoassay.  Opsonized and washed erythrocytes (ER, EIgG, and EIgM) (1.25 
X  l0 T E/tube  in 50 ~1 of BDVEA) were mixed with saturating amounts of ~25I-anti-C3c 
or a~SI-anti-C3g  and were incubated for 15 min at 22°C. After the incubation period, 5 
x  106 E  were  layered onto 0.2  ml of a  4:1  (vol/vol) solution  of dibutyl phthalate  and 
dinonyl phthalate in a 0.5 ml microfuge tube. The tubes were centrifuged for 1 rain in a 
Beckman Microfuge B (Beckman Instruments, Inc., Palo Alto, CA) and then frozen in an 
ethanol-dry ice bath. The cells in the pellet were clipped and then counted in a gamma 
counter (1185 series; Nuclear-Chicago, Des Plaines, IL). 
50 ~! of opsonized Y  containing  1 x  107 cells were aliquoted  into  1.5-ml  microfuge 
tubes, saturating amounts of ~SI-anti-C3c or ~2~I-anti-C3g  were added, and the mixture 
was incubated for 15 min at 22°C. Y were washed four times in 1 ml of cold BDVEA to 
remove unbound antibody, and the yeast pellet was clipped into tubes for determination 
of bound radioactivity. 
50 ~1 of opsonized bacteria  were incubated  with  labeled  antibodies in  15-ml conical 
centrifuge tubes.  At the end of the  15 min incubation period, the bacteria were diluted 
with  10 ml of BDVEA. After mixing, 5 ml of bacteria were collected on 0.22 #m filters 
(Millipore/Continental Water Systems, New Bedford, MA). The filters were washed with 
20 ml BDVEA and then placed into tubes for determination of bound radioactivity. The NEWMAN  AND  MIKUS  1417 
number of bacteria per filter was calculated based on colony counts obtained from the 
sample removed at the beginning of each experiment. 
Deposition of m5I-C3  on Yeast and Bacteria.  Purified human C3 (30) was labeled with 
~25I in the same manner as the monoclonal antibodies.  Yeast or heat-killed bacteria (5.5 
x  10  s) were centrifuged, and the pellets were mixed with 36 ug of '2~I-C3 and 25% serum 
in VBS  ++ (final volume, 0.5 ml). Opsonization was allowed to proceed for 60 min at 37°C. 
At the end of the incubation period, the bacteria were washed in BDVEA, and the yeast 
were washed in VBS  ++. The bacteria and yeast were resuspended to 0.5 ml in the wash 
buffer, and a 20 el sample was removed to determine the amount of bound C3. Based on 
the counts per minute, an aliquot of yeast or bacteria was pelleted in a microfuge tube to 
produce a  pellet containing 3-5 x  105 cpm. To determine the molecular weight of the 
bound '25I-C3 fragments, the pellets were solubilized in 125 #i of 100 mM diethanolamine, 
pH 11.7, containing I00 mM NaCI, 1% SDS, and 8 M urea, for 1 h at 45°C to elute the 
membrane-bound 1251-C3 fragments (31). The pH of the  t25I-C3  fragment mixture was 
neutralized  to  pH  7  with  1  N  HCI,  and  dithiothreitol  (DTT)  was  added  to  a  final 
concentration of 100 raM. The mixture was then diluted with 65 #1 of 25 mM Tris-HCl, 
pH 6.8 containing 2%  SDS,  100 mM DTT, and 8  M  urea, and boiled for 5 min; 75% 
glycerol containing 0.001%  bromophenol  blue was added so that  the final  volume was 
300  #1.  Similarly  treated  ~2~I-C3 was  used  as  a  control.  From  each  tube  an  aliquot 
representing  5  x  104 cpm was removed and electrophoresed  in 9% polyacrylamide gel 
slabs (32). The gels were stained with Coomassie Blue, dried onto a sheet of chromatog- 
raphy paper  (Whatman,  Inc., Clifton,  NJ),  placed on preflashed  (33)  X-Omat AR film 
(Eastman Kodak Co., Rochester, NY), and incubated at -70°C for 6 h. After developing 
the x-ray film, the positions of the stained molecular weight markers were marked on the 
fi!  m,  and  the  molecular  weight  of the  ~2~I-C3 fragments  were  calculated  from  their 
mobilities relative to the standards. 
Data.  In all experiments reported, data are expressed as the number of molecules of 
antibody bound per particle or CFU.  In experiments with heat-killed bacteria,  the data 
are expressed as antibody molecules bound per bacterium. Specific activity for the labeled 
antibodies was always corrected for decay of x25I. Data represent the mean of two to three 
experiments. 
Results 
The  specificity  of monoclonal  anti-C3c  and  anti-C3g  is  illustrated  in  Fig.  1. 
Anti-C3c binds to the C3c portion  of fixed C3b.  However,  the antigenic  deter- 
minant  recognized  by  anti-C3g  is  not  exposed  in  bound  C3b  (27,  28).  When 
bound C3b is cleaved to iC3b, both of the monoclonal antibodies recognize and 
bind  to  their  respective  antigenic  determinants  on  this  fragment.  If iC3b  is 
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FIGURE  1.  Binding of monoclonal antibodies  anti-C3c and anti-C3g to particle-bound  frag- 
ments of C3. Anti-C3c, but not anti-C3g, bound to particle-bound C3b. Conversion of C3b to 
iC3b resulted  in equivalent  binding by both antibodies.  Conversion of iC3b to C3d,g resulted 
in the loss of C3c into the fluid phase. Thus, anti-C3g, but not anti-C3c, binds to this remaining 
fragment. Conversion of C3d,g to C3d resulted  in the loss of binding by anti-C3g. The arrow 
over the alpha chain represents the position of the metastable  binding site. 1418  C3b  AND  iC3b  ON  PARTICULATE  ACTIVATORS  OF  COMPLEMENT 
further cleaved to C3d,g, the binding of anti-C3c is abrogated due to the loss of 
C3c antigen, but anti-C3g binding remains constant. Final cleavage of C3d,g to 
C3d abrogates the binding of anti-C3g. Thus, radiolabeled anti-C3c and anti- 
C3g  were  used  to  quantitate  the  total  number  of bound  C3  molecules and 
determine which C3 fragments were present. 
CP Activators.  EIgM and EIgG were used to assess  deposition of C3b  and 
conversion to iC3b,  C3d,g or  C3d  by the classical  pathway in  human serum. 
Serum from a patient with C7D (24) was used to avoid lysis of the erythrocytes. 
The deficiency of C7  is the only defect detected in  this patient's serum,  and 
comparison  of this  serum  with  PHS  in  the  opsonization of Y  gave  identical 
results. EIgM and EIgG were incubated in different concentrations of serum for 
20  min at  37°C,  and then  incubated with  the  two  monoclonal antibodies as 
described  in  Materials  and  Methods.  In  Figs.  2-8,  the  total  number  of C3 
molecules bound is represented by anti-C3c. The number of bound iC3b mole- 
cules is  represented by anti-C3g.  The  difference between the  number of C3 
molecules detected by anti-C3g and anti-C3c represents bound but unconverted 
C3b. 
As shown in Fig. 2, the number of molecules of C3 bound to EIgM and EIgG 
was a function of the serum concentration. >100,000  molecules of C3 became 
bound to EIgM incubated in 5%  PHS, while >80,000 molecules of C3 became 
bound to EIgG.  For both EIgM and EIgG,  there was complete conversion of 
bound C3b to iC3b at all serum concentrations tested. There was no evidence 
of cleavage of iC3b to C3d,g or C3d. 
Serum deposition of C3b and conversion to iC3b on EIgM and EIgG was next 
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FIGURE  2.  Quantitation  of C3b and iC3b  on  EIgM  and  EIgG as a  function of the serum 
concentration.  1 ×  10  s E/ml in VBS ++ was mixed with an equal volume of different concen- 
trations of C7-deficient serum diluted in VBS  ++. The  E  were  then incubated for  20  rain  at 
37°C.  Control  tubes contained  E  plus buffer only.  At the end of the incubation period,  E 
were diluted in BDVEA, washed three times, and then resuspended in BDVEA to 5-7  ×  l0 s 
E/ml. Bound C3b and iC3b were quantitated with the radioiodinated  monoclonal antibodies 
anti-C3c  and  anti-C3g  as  described  in  Materials  and  Methods.  Data  are  expressed as  the 
number of molecules of antibody bound per E. NEWMAN  AND  MIKUS  1419 
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FIGURE  3.  Quantitation of C3b and iC3b on  EIgM and  EIgG as a  function of the time of 
incubation.  The conditions of incubation  were the  same as  in  Fig.  2,  except  that  the  final 
serum concentration was 2%. 
occurred at  15 min for both CP activators incubated in 2% serum. In addition, 
conversion of bound C3b to iC3b occurred immediately, even as more C3b was 
being bound to the erythrocytes. Again, there was no evidence of conversion of 
iC3b to C3d,g, even after 2 h of incubation in serum. Erythrocytes incubated in 
serum  >30  min  showed  some  decline  in  the  number  of C3  molecules  that 
remained surface bound.  This was due to the release of intact C3  and not C3 
fragments, since the number of bound C3 molecules detected by both anti-C3c 
and anti-C3g decreased in parallel. This phenomenon has also been observed by 
other investigators (34, 35). 
AP Activators.  The number of C3b and iC3b bound to ER in C7D serum was 
determined in the presence and absence of Mg-EGTA, due to the presence of 
"natural"  antibodies  in  human  serum  to  these  cells.  Mg-EGTA  was  used  to 
prevent the  activation of the  CP  by  chelating  Ca  ++.  This  reagent  still  allows 
activation of the AP,  which  only requires Mg  ÷+ (36).  Fig.  4  shows the  results 
obtained when ER were incubated in different concentrations of serum for 20 
rain  at  37°C,  with  and  without  Mg-EGTA.  In  both cases,  C3  deposition was 
dependent on serum concentration. At all serum concentrations tested, greater 
numbers of C3 molecules bound to ER when both the CP and AP were activated 
(i.e.,  without  Mg-EGTA).  In  the  absence  of Mg-EGTA,  only 3%  serum  was 
required to bind 4-5  x  104 molecules of C3/E; in the presence of Mg-EGTA, 
6%  serum  was  required.  The  percent  conversion of C3b  to  iC3b  was  also 
dependent on the serum concentration. As the serum concentration increased, 
so did the percent of bound iC3b. 
The deposition of C3b and conversion to iC3b on ER as a function of time is 
shown in Fig. 5. When both the CP and AP were operative (no Mg-EGTA, 2% 
serum),  maximum  C3  deposition occurred by  30  min.  Conversion of C3b  to 
iC3b was evident at 10 min and continued throughout the 2 h incubation period. 
At the  end of 2  h,  79%  of bound C3  was  iC3b.  When  E~  were incubated in 
serum and used the AP only (Mg-EGTA, 6% serum), C3 deposition was complete 
by 30 min. Again,  conversion of C3b to iC3b and deposition of more C3  were 1420  C3b  AND  iC3b  ON  PARTICULATE  ACTIVATORS  OF  COMPLEMENT 
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FIGURE 4.  Quantitation of C3b and iC3b on ER as a  function of serum concentration. The 
conditions of incubation were  the same as those described  in  Fig.  2.  ER were  incubated in 
different concentrations of C7-deficient serum in the absence and presence of 0.1  mM MgCI~ 
+  0.4 mM EGTA (Mg-EGTA). 
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FIGURE  5.  Quantitation of C3b and iC3b on ER as a  function of the time of incubation,  The 
conditions  of incubation  were the same as in Fig. 2. A  final concentration of 2% C7-deficient 
serum  was  used  in  the absence of Mg-EGTA;  6%  serum  was  used  in  the presence of Mg- 
EGTA. 
concurrent  events.  After  30  min,  there  was  no  further  conversion  of C3b  to 
iC3b, and iC3b made up 52%  of the total C3 bound. 
Yeast (Y) was also studied as an AP activator. Fig.  6  shows the deposition and 
conversion of C3b  onto Y  as a  function of serum concentration.  At 50%  serum 
concentration,  maximal  C3  deposition  occurred with almost 9  x  104 molecules 
of C3  bound per Y.  84%  of bound  C3  was iC3b  in  50%  serum; 67%  of bound 
C3  was iC3b  in  25%  serum.  The examination  of C3  deposition and conversion 
as a  function  of time in  50%  serum  is shown in  Fig.  7.  Maximal  C3  deposition 
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FIGURE  6.  Quantitation of  C3b  and iC3b on Y as a function of the serum concentration. 1.5 
x  109  Y/ml in  PBSA  was mixed with an equal volume of different concentrations of PHS 
diluted in VBS  ÷÷. The Y were then incubated for 20 min at 37°C. A  control tube contained 
Y  plus buffer only.  At the end of the incubation period, the Y  were washed three times in 
cold PBS, and then were resuspended to 2  ×  10S/ml in BDVEA. Bound C3b and iC3b were 
quantitated with the radioiodinated monoclonal antibodies anti-C3c and anti-e3g as described 
in Materials and Methods. 
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FIGURE  7.  Quantitation of C3b and iC3b on Y  as a  function of the time of incubation. The 
conditions of incubation were the same as in  Fig.  6.  The  final concentration of serum was 
50%. 
iC3b  was also  very  rapid.  94%  of bound  C3  that was  eventually  converted  to 
iC3b was completed  within  15 min. At 30 min, 87% of bound C3 was iC3b.  No 
significant changes in total bound C3  or the percent of iC3b occurred between 
30 min and 2  h. 
Table I is a comparison of the concentration of serum required to fix between 1422  C3b  AND  iC3b ON  PARTICULATE ACTIVATORS  OF  COMPLEMENT 
TABLE  I 
Concentration of Serum Required for Fixation of 4-5 × 104 C3 
Molecules per Particle 
Serum  Particle  Addition  concentration 
% 
EIgM  --  2 
EIgG  --  2 
ER  --  3 
ER  Mg-EGTA  6 
Y  --  25 
Y  Mg-EGTA  25 
Particles  and  serum  were  mixed  and  incubated  for  20  min  at  37°C. 
Particles were washed in buffer and the number of bound C3b molecules 
was determined  as described in  Materials and  Methods.  Mg-EGTA  was 
added  to  the  serum  so  that  the  final  concentration  in  the  incubation 
mixture was 1 mM Mg  ++ and 4 mM EGTA. 
4 and 5 ×  104 C3 molecules per particle. For EIgM, EIgG, and ER (in the absence 
of Mg-EGTA), <5% serum was required, and only 6% serum was required for 
ER in the presence of Mg-EGTA. Under the conditions of opsonization used for 
Y, these particles required 25% serum to achieve similar numbers of molecules. 
The presence or absence of Mg-EGTA did not effect the number of C3 molecules 
bound per Y, or the percent of bound iC3b. 
Finally, we examined serum deposition of C3 and conversion to iC3b in five 
different species of bacteria. The species chosen were those that are pathogenic 
and require phagocytosis by professional phagocytes to be cleared from the host 
(37). Bacteria were grown to log phase, washed in buffer, and then incubated in 
neat PHS for varying periods up to 2  h. The number of molecules of C3b and 
iC3b bound to the bacteria (Fig. 8) was determined as described in Materials and 
Methods.  The total number of bound  C3  molecules per CFU  on the different 
species of bacteria ranged from 3 ×  104 molecules on H. influenzae type b to 6.6 
×  104  molecules  on S.  pneumoniae  type  3.  Opsonization  was  usually  complete 
after 60  min of incubation  in serum,  the main  exception being S.  pneumoniae. 
The  most  interesting  aspect  of these  experiments  was  the  noticeable  lack  of 
conversion of bound C3b to iC3b. At 60 min, the average percent conversion of 
C3b to iC3b was  only 21%  (range,  16-28%).  In a  separate  set of experiments 
(Table II), heat-killed bacteria were used to assess the role of the AP in opsoni- 
zation of these bacteria, and to determine what effect, if any, soluble, purified 
human  erythrocyte CR1  (38)  might  have  on  the  ratio  of C3b  to  iC3b  (or  to 
C3d,g).  Bacteria were added  to either PHS,  PHS heated to 56°C  for 60  min, 
PHS containing Mg-EGTA, or PHS containing 10 #g of CRy, and were incubated 
for 20 min at 37°C. The bacteria were then washed, and bound C3b and iC3b 
was  quantitated  as  before.  Bacteria  incubated  in  heat-inactivated  serum  had 
background  counts <5%  of that  obtained  with  PHS.  Except for H.  influenzae 
and S. pneumoniae,  the total number of bound C3  molecules per bacterium was 
the  same  whether  the  bacteria were viable or dead.  Also,  on four out of five 
bacterial strains, the percent of iC3b per bacterium was the same for viable and 
dead bacteria.  S.  aureus  was  the  exception, with  58%  iC3b  on dead and  22% NEWMAN  AND  MIKUS  1423 
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FIGURE  8.  Quantitation of C3b and iC3b on five different strains of bacteria as a  function 
of the time of incubation.  Log phase bacteria were aliquoted  into several tubes and washed 
twice in saline.  1 nd of PHS was added to each pellet of bacteria, the bacteria were vigorously 
resuspended, and the tubes were incubated at 37 °C for various periods of time. At the end of 
the incubation period, bacteria were washed twice in saline and then resuspended  to 2  rnl in 
BDVEA. Bound C3b and iC3b were quantitated with the radioiodinated monoclonal antibodies 
anti-C3c and anti-C3g, as described in Materials and Methods. 
iC3b  on  viable  bacteria.  Overall,  the  addition  of Mg-EGTA  to PHS  did  not  have 
a  significant  effect  on  the  total  number  of C3  molecules  bound  per  bacterium  or 
the  percent  of  iC3b.  However,  opsonization  of S. pneumoniae  in  the  presence  of 1424  C3b  AND iC3b ON  PARTICULATE ACTIVATORS  OF  COMPLEMENT 
TABLE II 
Quantitation of C3b and iC3b on Heat-killed Microorganisms 
Molecules per bacterium (x l 0  4)  Percent 
Microorganism  Addition* 






None  4.0  2.9  1.1  27 
Mg-EGTA  6.9  5.0  1.9  27 
CRI  4.1  2.9  1.2  29 
None  2.4  1.0  1.4  58 
Mg-EGTA  3.3  1.4  1.9  57 
CR1  2.7  1.3  1.4  52 
None  5.1  3.6  1.5  29 
Mg-EGTA  5.2  3.4  1.8  35 
CR1  4.6  3.0  1.6  35 
None  4.0  3.0  1.0  25 
Mg-EGTA  3.3  2.3  1.0  30 
CRI  4.8  3.9  0.9  19 
None  5.8  3.8  2.0  34 
Mg-EGTA  5.1  2.5  2.6  51 
CRI  5.4  3.4  2.0  37 
* Bacteria were incubated for 20 min at 37°C in neat PHS only, PHS containing 0.1 M MgC12/0.4 
M EGTA, or PHS containing 10 ~g of purified human erythrocyte CR1. 
The number of bound C3b molecules was determined by subtracting the number of molecules of 
anti-C3g bound from that obtained with anti-C3c. (See Fig. 1 and first paragraph in Results). 
Mg-EGTA appeared  to result  in  a  greater percent  of bound iC3b than  in  the 
absence of Mg-EGTA. Addition of CR~  to PHS did not significantly affect the 
total number of C3 molecules bound or the percent of iC3b, nor did it cause the 
degradation of iC3b to C3d,g. 
In a  previous  study  (30),  we  examined  the  molecular  form of C3  on  EC3b 
after treatment with various concentrations of factors H  and I. In these experi- 
ments,  the  monoclonal antibody  data  revealed  that  iC3b  but  not  C3d,g  was 
formed under isotonic conditions. Conversion of C3b to C3d,g occurred only if 
the reaction with factors H  and I took place in a  buffer of low ionic strength or 
in the presence of purified CR1. Conversion of EC3b to EC3d,g was accompanied 
by a  decrease  in  binding of anti-C3c and  was confirmed in  experiments  using 
125I-C3 to prepare  EC3b, in which the C3  fragments formed were analyzed by 
SDS-PAGE and autoradiography. 
To  confirm that  only C3b  and  iC3b  become fixed  to  the  surface  of Y  and 
bacteria opsonized in normal human serum,  ~zsI-C3 was mixed with Y and three 
of the strains of bacteria (E.  coli,  S.  aureus, and H.  influenzae)  in  25% serum in 
VBS  ++. Opsonization was allowed to proceed for 60 min at 37°C, and then the 
bacteria and Y were processed for SDS-polyacrylamide gel electrophoresis (SDS- 
PAGE)  and  autoradiography as  described  in  Materials  and  Methods.  Fig.  9B 
shows the  a  and/3 chains of 125I-C3 run  as a  control.  Fig.  9,  C-F show the  C3 
fragments eluted  from the S.  aureus,  E.  coli,  H.  influenzae,  and Y,  respectively. 
The intact  1 15,000  kD a'  chain present on all four particles  represents  bound NEWMAN  AND  MIKUS  1425 
FIGURE 9.  SDS-PAGE/autoradiography of t25I-C3  fragments eluted from serum-opsonized 
Y and bacteria. (A) Position of the molecular weight markers. (B) Native l~sI-C3.  (The extra 
band at 48,000 mol wt is a minor contaminant of the C3 preparation that did not show up on 
previous  Coomassie  Blue-stained  gels.  It  did  not  appear  in  any  of the  other  tracks,  and 
therefore, did not bind to the Y or bacteria). (C-F) Eluted 1~5I-C3 fragments from S. aureus, 
E. coli, H. influenzae,  and Y, respectively. The bacteria and Y were opsonized in 25% serum 
for 60 min at 37°C in the presence of 36 t~g of l~sI-C3.  The bound l~sI-C3 fragments were 
eluted and then analyzed under  reducing conditions on  9%  polyacrylamide gels.  The  gels 
were stained and prepared for autoradiography as described in Materials and Methods. 5  x 
104 cpm were run in each track. 
C3b. The 68 kD fragment from the 0~' chain represents bound iC3b. The 43 kD 
band of the a' chain of iC3b is not seen in Fig. 9 because it is poorly labeled by 
the  iodination  procedure  (14).  However,  the  43  kD  band  was  observed  on 
overexposed x-ray film (not shown).  No bands were seen at 41  kD even after 
overexposure of the x-ray film, indicating that no C3d,g was formed. 
Discussion 
Two  monocional antibodies, anti-C3c and anti-C3g,  were  used  to  examine 
serum deposition of C3b and its conversion to iC3b on particulate activators of 
the complement system. The particles studied activated both the CP and the AP. 
Human serum  pooled  from  six  normal  donors (PHS)  was  used  to  study the 
opsonization of Y and bacteria, while serum from a patient with C7 deficiency 
(24) was used to study the opsonization of EIgM, EIgG, and ER. This C7-deficient 
serum performed identically to PHS in the opsonization of Y.  The validity of 
using anti-C3c and anti-C3g to define the ratio of C3b/C3bi on Y and bacteria 
was confirmed using 125I-C3 and SDS-PAGE and autoradiography to show that 
no C3d,g was formed on these particles. Thus, the measurements obtained with 
anti-C3g represented only bound iC3b,  and,  therefore, the amount of bound 
C3b could be calculated by subtracting the values obtained with anti-C3g from 
the values obtained using anti-C3c. We have shown previously that this is also 
true for erythrocytes (30). 
C3b deposition and conversion to iC3b on the CP activators EIgM and EIgG 
was a very rapid and almost simultaneous process. Bound C3b was converted to 
iC3b even as more C3b was being bound to the erythrocytes' surfaces. These 
data dramatically illustrate the total inability of the cell membrane of sheep E to 
provide any protection for bound C3b from serum factors H and I, and corrob- 
orate well with the original studies of Fearon (23). 1426  C3b  AND  iC3b  ON  PARTICULATE  ACTIVATORS  OF  COMPLEMENT 
In contrast, particles that activate the AP were quite varied in their ability to 
protect bound C3b from factors H and I. On Y, the total number of C3 molecules 
bound and the ratio of C3b to iC3b  were the same in both the presence and 
absence of Mg-EGTA (82% iC3b). However, the presence of Mg-EGTA during 
the opsonization of Ea did effect the ratio of C3b to iC3b. After 1 h of incubation 
in 4% serum, 74% of bound C3 was iC3b in the absence of Mg-EGTA, compared 
with only 52% in the presence of Mg-EGTA. Thus, when both the CP and AP 
were operative with ER, more C3b was converted to iC3b than when only the 
AP was activated.  These differences may be due  to C3b binding to different 
parts  of the  Ea  membrane.  C3b  that  bind  via  the  CP  may bind  to  the  Ea 
membrane in an environment totally unprotected from factors H  and I, while 
C3b  that bind via the AP  may adhere to a  part of the membrane where it is 
partially protected. However, C3  deposition via the CP does not appear to be 
the main factor controlling the conversion of C3b to iC3b. Rather, the surface 
of the particle appears to be the key regardless of which C pathway is activated. 
Thus,  pneumococci incubated in  normal serum contain mainly C3b  on  their 
surface whether or not IgM anti-pneumococcal antibody was added to the serum 
(39). 
From our experiments with EIgM, EIgG, ER, and Y, four important conclu- 
sions can be made.  First, the deposition of C3b and its conversion to iC3b on 
particulate activators of the complement system are concurrent events. C3b is 
cleaved to iC3b by factors H and I at the same time that more C3 is cleaved to 
C3b by the C3 convertase. Second, although activators of the AP can provide an 
environment for C3b that favors the binding of factor B over factor H (21, 22), 
50-80%  of bound C3b may still  be converted to iC3b.  Third, at least on the 
particles studied, and  under the isotonic conditions used,  iC3b  is not cleaved 
further to C3d,g or C3d. C3d,g does appear  to be the final C3  fragment on 
human  erythrocytes from  patients  with  chronic  cold  agglutinin disease  (40). 
Finally, some bound C3b remains on activators of the AP, even after prolonged 
incubation  in  serum;  this  ratio  of C3b  to  iC3b  is  mainly dependent on  the 
particle. 
This  last  conclusion  is  particularly  significant  with  respect  to  the  results 
obtained with the five different species of bacteria (E.  coti, S. pneumoniae  type 
III, S. pyogenes,  S.  aureus, and H.  influenzae type b).  These bacteria all activate 
the AP (41-45) and require phagocytosis for removal from the host (37).  When 
they were incubated in serum for up to 2  h, only 16-28%  of bound C3b was 
converted to iC3b, and no C3d,g was detected. The addition to the serum of 
Mg-EGTA (so  that only the AP was activated) or purified human erythrocyte 
CR1  (38), which has been shown to be a cofactor for factor I (15,  16), did not 
significantly affect the total number of C3 molecules bound or the ratio of C3b 
to iC3b, and did not cause the formation of C3d,g. This preparation of CRl had 
been shown previously (30)  to promote the cleavage of sheep E-bound C3b to 
C3d,g in isotonic human serum. Thus, it would appear that the bacteria-bound 
C3b  was resistant to factor I,  even when  CR~  was  provided as a  cofactor.  In 
experiments witb S.  pneumoniae  (types 7  and  12,  and  unencapsulated R36A), 
Brown et al. (39)  also found that only small amounts of C3b were converted to 
iC3b, as determined by the binding of 125I-labeled bovine conglutinin to serum- 
opsonized bacteria. In addition, little iC3b was formed even when the bacteria NEWMAN AND  MIKUS  1427 
were coated with IgM anti-pneumococcal antibody before incubation in serum. 
This  latter  observation  further  emphasizes  the  importance  of  the  particle's 
surface in determining the amount of C3b that is converted to iC3b, regardless 
of which complement pathway is activated. 
In the experiments with bacteria we have not attempted to determine whether 
the C3b or iC3b molecules were bound to the bacterial cell wall or capsule, nor 
have  we tried  to  determine  if the  ratio  of C3b  to  iC3b  varies  with  different 
strains  within  a  species.  However,  in  experiments  with  pneumococci,  other 
investigators  have  reported  that  C3b becomes fixed to  the  pneumococcal  cell 
wall during activation  of the AP (46) and that,  in the presence of anticapsular 
antibody, C3b becomes fixed to the pneumococcal capsule only via the CP (47). 
The predominant form of bound C3 on the pneumococci appears to be C3b, on 
both the cell wall and  the capsule (39).  Studies with S. aureus have also found 
that  C3  binds  to  the cell  wall  of encapsulated  organisms  incubated  in  normal 
human serum (48), but that C3 becomes bound to the capsule in immune serum 
(49).  In our experiments,  most of the bound C3b is probably on the cell wall; 
this  could  be  confirmed  by  using  the  monoclonal  anti-C3c  and  anti-C3g  in 
immunoelectron  microscopy  experiments.  Finally,  although  different  strains 
within a particular species have been reported to differ in their ability to activate 
C, it is likely that these differences affect the number of C3 molecules bound but 
not necessarily the ratio of C3b to iC3b. This is supported by recent studies (50) 
with three strains of Salmonella that differed from one another in the chemical 
structure of their O-polysaccharide. C3 deposition resembled C3 consumption in 
rate and extent, differing for surfaces with different O-polysaccharides. However, 
the ratio  of bacteria-bound C3b to iC3b was the same for all three  strains.  In 
addition,  Weis et al.  (51) reported  that  both M + and  M- group A  streptococci 
contained  bound C3b and  iC3b (but not C3d,g)  when  they were opsonized in 
normal human serum. Interestingly, the C3b and iC3b on the M + strain did not 
promote binding  of the bacteria  to erythrocyte CR1  or to polymorphonuclear 
cells CR~ or CR3, suggesting that the M protein was most likely responsible for 
the resistance of these bacteria to phagocytosis. 
As they pertain to the process of inflammation,  these results suggest that C3b, 
and  not  iC3b,  may  be  the  predominant  form  of bound  C3  encountered  by 
neutrophils and monocyte/macrophages.  At the very least, phagocytes may use 
both  CR1  (C3b)  and  CR3  (iC3b),  in  addition  to  Fc  receptors,  to  promote 
phagocytosis and the destruction of pathogenic microorganisms. 
Summary 
Monocional  antibodies  were  used  to  determine  the  number  and  molecular 
form  of C3  bound  to  particulate  activators  of the  complement  (C)  system by 
human  serum.  Sheep erythrocytes (E) coated with IgM (EIgM) and IgG (EIgG) 
were  used  to  study  activation  of the  classical  pathway  (CP).  Yeast  (Y),  rabbit 
erythrocytes  (ER), and  five  species  of bacteria  (Escherichia  coli, Staphylococcus 
aureus,  Streptococcus pneumoniae type  3,  Streptococcus pyogenes, and Hemophilus 
influenzae type b) were used to study activation of the alternative pathway (AP). 
The deposition of C3b onto EIgM and EIgG incubated in C7-deficient human 
serum was dependent on the serum concentration.  At all serum concentrations 
tested, there  was complete conversion of C3b to iC3b.  Kinetic analysis of C3b 1428  C3b  AND  iC3b ON  PARTICULATE  ACTIVATORS  OF  COMPLEMENT 
deposition and conversion to iC3b indicated that these events occurred almost 
simultaneously;  the  reaction  was  completed by  15  min.  The deposition  of C3 
onto the AP activators ER and  Y  was also dependent on serum  concentration, 
and ER, but not Y, required the presence of Mg-EGTA and thus the activation 
of only the AP. C3b deposition and conversion to iC3b on Y was complete in  15 
min, with 82% of bound C3 converted to iC3b. For ER, maximum C3 deposition 
required 30 min in both the presence and absence of Mg-EGTA. However, after 
1  h  of incubation,  74%  of bound  C3  was  iC3b  in  the  absence  of Mg-EGTA, 
compared  with  only  52%  in  the  presence  of Mg-EGTA.  Thus,  even  on  AP 
activators, a large portion of C3b may be converted to iC3b, and this conversion 
is probably controlled by elements on the particle's surface. 
Studies  with  the  five species  of bacteria  yielded similar  results.  ~3-5  x  104 
molecules of C3  were bound per microorganism, with opsonization being com- 
pleted in  30  min.  Remarkably,  only  16-28%  of bound  C3  was in  the form of 
iC3b,  even after 2  h  of incubation.  The presence or absence of Mg-EGTA, or 
the addition of purified CR~  to the reaction mixture, did not significantly effect 
the ratio of C3b to iC3b.  Finally, SDS-PAGE and autoradiography of particle- 
bound  lz5I-C3  fragments  confirmed that  there  was  no  conversion of iC3b  to 
C3d,g or C3d. The data obtained about the opsonization of bacteria suggest that 
the predominant  form of C3  that  is  encountered by inflammatory phagocytes 
may be C3b. 
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